HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals.

MLA

van Griensven, Johan, et al. “HIV-1 Protease Inhibitors for Treatment of Visceral Leishmaniasis in HIV-Co-Infected Individuals.” The Lancet. Infectious Diseases, vol. 13, no. 3, Mar. 2013, pp. 251–59. EBSCOhost, https://doi.org/10.1016/S1473-3099(12)70348-1.

APA

van Griensven, J., Diro, E., Lopez-Velez, R., Boelaert, M., Lynen, L., Zijlstra, E., Dujardin, J.-C., & Hailu, A. (2013). HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals. The Lancet. Infectious Diseases, 13(3), 251–259. https://doi.org/10.1016/S1473-3099(12)70348-1

Chicago

van Griensven, Johan, Ermias Diro, Rogelio Lopez-Velez, Marleen Boelaert, Lutgarde Lynen, Ed Zijlstra, Jean-Claude Dujardin, and Asrat Hailu. 2013. “HIV-1 Protease Inhibitors for Treatment of Visceral Leishmaniasis in HIV-Co-Infected Individuals.” The Lancet. Infectious Diseases 13 (3): 251–59. doi:10.1016/S1473-3099(12)70348-1.